Danaher stock remains supported by earnings and margins

Danaher Corp. (ISIN US2358511028) is trading around $196.74, with the stock valued at roughly $141.4 billion as of 20 July 2026. The latest annual report gives investors a clear baseline: 2025 revenue of $23.9 billion, adjusted diluted net earnings per share of $7.66, and an adjusted operating margin of 27.3%.

Revenue and margin base

The 2025 revenue figure of $23.9 billion matters because it sits alongside a 5.8% decline in core revenue for the year, according to Danaher’s annual report. That combination shows a business that still converted scale into profit, even as underlying demand softened in parts of the portfolio.

Adjusted operating profit in 2025 reached 27.3% of sales, which is high for a diversified life sciences and diagnostics group. Adjusted diluted EPS of $7.66 provides a second anchor for valuation work, especially when compared with the $196.74 share price visible on 20 July 2026.

2025 delivered less volume

The same report says core revenue fell 5.8% in 2025, a useful comparison point because it shows the operating backdrop was weaker than the headline sales line alone suggests. Investors often focus on that gap: revenue still came in at $23.9 billion, but the underlying trend moved lower.

That makes margins the key variable. With a 27.3% adjusted operating margin, Danaher kept a strong earnings profile despite the 5.8% core revenue decline.

Market value and earnings

At about $141.4 billion of market capitalization as of 20 July 2026, Danaher still sits in the large-cap bracket that investors usually associate with defensible cash generation and a broad portfolio of recurring revenue streams. The stock price near $196.74 also puts a practical frame around the 2025 EPS of $7.66.

That gap between earnings and equity value matters because it is the fastest way to translate the report into market terms. On the evidence available here, the question is less about size and more about whether the company can re-accelerate core revenue after the 5.8% 2025 decline.

Diagnostics and life sciences

Danaher’s portfolio remains centered on diagnostics and life sciences tools, which is why earnings quality often matters more than a single quarter’s sales headline. The 2025 report numbers suggest the group kept a strong profitability profile even as the operating environment stayed uneven.

For investors, the most useful detail is the margin: 27.3% adjusted operating margin in 2025 leaves room for earnings leverage if core revenue stabilizes. A 5.8% core revenue decline is the counterweight that still needs to be watched against that profit base.

Share price near earnings power

Danaher stock traded around $196.74 as of 20 July 2026, with market capitalization near $141.4 billion. Against 2025 adjusted diluted EPS of $7.66, the market is still assigning a premium to the company’s cash flow and margin profile.

The current setup is straightforward: revenue of $23.9 billion, adjusted operating margin of 27.3%, and core revenue down 5.8% in 2025 form the latest quantified backdrop for the stock. That mix makes margin resilience the central metric in any fresh read on Danaher.